Adequate evidence to support improved outcomes in depression by primary care physicians compared to psychiatrists when using combinatorial pharmacogenomics

Affiliations

¹ Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Assurex Health Ltd., Toronto, ON, Canada.
² Assurex Health Ltd., Toronto, ON, Canada.
³ Thornhill Medical Centre, Toronto, ON, Canada.
⁴ Assurex Health, Mason, OH, USA.
⁵ Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Electronic address: Jim.Kennedy@camh.ca.

Comment

Julie-Anne Tanner et al. J Psychiatr Res. 2019 Oct.

. 2019 Oct:117:151-152.

doi: 10.1016/j.jpsychires.2018.10.016. Epub 2018 Nov 15.

¹ Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Assurex Health Ltd., Toronto, ON, Canada.
² Assurex Health Ltd., Toronto, ON, Canada.
³ Thornhill Medical Centre, Toronto, ON, Canada.
⁴ Assurex Health, Mason, OH, USA.
⁵ Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Electronic address: Jim.Kennedy@camh.ca.

No abstract available

Comment on

The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.
Rosenblat JD, Lee Y, McIntyre RS. Rosenblat JD, et al. J Affect Disord. 2018 Dec 1;241:484-491. doi: 10.1016/j.jad.2018.08.056. Epub 2018 Aug 14. J Affect Disord. 2018. PMID: 30149336 Review.